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Abstract  
The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA 
(CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to 
validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition 
of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the 
cycle resulted in loss of infectious progeny for six unique clinical isolates representing 
different serovars.  This supports the potential for CtHtrA to be a clinically relevant target for 
development of new therapeutics and suggests the importance of further investigation of 
JO146 as a lead compound.  
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1. Introduction 
 
Chlamydia (C.) trachomatis is an obligate intracellular bacterial pathogen and is a 
commonly reported bacterial sexually transmitted pathogen worldwide. In the United States, 
over 1.4 million cases of C. trachomatis infection were reported in 2012, the highest number 
of cases ever reported to CDC for any condition [1].  
Currently, the recommended first line of treatment for uncomplicated genital C. 
trachomatis infections is a single 1.0 g oral dose of the macrolide antibiotic azithromycin [2]. 
However, a number of recently published studies challenge the efficacy of azithromycin 
therapy for chlamydial infections [3-6]. Batteiger and co-workers [6] conducted a cohort 
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study among adolescent women and used a classification algorithm to characterize treatment 
outcomes among the study subjects after directly observed azithromycin treatment. Among 
women with paired episodes of chlamydial infections, 8% were probable treatment failures. 
A partner treatment study conducted by Golden and co-workers [7] reported that 8% (22 of 
289 originally treated for Chlamydia) of cases treated reported no sexual intercourse after 
treatment and were classified as treatment failures. These studies suggest the possible future 
need for improved anti-chlamydial therapies.  
Our group identified a serine protease inhibitor, JO146, against C. trachomatis High 
Temperature Requirement A (CtHtrA) [8-11]. JO146 was found to be lethal to C. trachomatis 
D when added at the mid-replicative stage of the chlamydial developmental cycle [8]. The 
addition of JO146 was lethal during reversion or recovery from penicillin persistence and 
during heat stress [12].  
Laboratory strains of C. trachomatis that are commonly used for biological 
experiments may not reflect the isolates currently infecting men and women [13]. Differences 
in genome dynamics, and virulence attributes and infectivity [14-16] may result in varying 
sensitivities to JO146 between recent clinical isolates and the type strains of C. trachomatis 
used for investigations to date. Therefore, we aimed to validate that CtHtrA is a clinically 
relevant target for potential future therapeutic development by testing the efficacy of the 
inhibitor JO146 against recent clinical isolates from women.  
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2. Materials and Methods 
 
2.1. Clinical isolates, Chlamydia culture and J0146 treatment conditions 
Six C. trachomatis clinical isolates were obtained and cultured from separate women 
enrolled in the Australian Chlamydia Treatment Study (ACTS) [17] (The Alfred Human 
Research Ethics Approval number 223/12). The isolates were designated as: 1-017(13) 
(serovar K), 1-079(1) (serovar G), 1-019(1) (serovar D), 1-048(1) (serovar E), 1-028(1) 
(serovar E), and 1-020(1) (serovar D). The isolates were cultured in McCoy B cells grown in 
Dulbecco’s minimal essential medium (DMEM, Life Technologies) supplemented with 5% 
fetal calf serum (Lonza), 10 µg ml
-1
 gentamicin (Invitrogen), 100 µg ml
-1
 streptomycin 
sulphate (Sigma), incubated at 37
o
C, 5% CO2. For the purposes of this study, JO146 
(chemical formula: C31H44N3O7P) was commercially synthesised [18]. The compound was 
synthesised, HPLC purified, and confirmed by MALDI-MS by GL Biochem (Shanghai, 
China).  
The impact of JO146 on Chlamydia was determined in McCoy B cells infected at a 
multiplicity of infection (MOI) of 0.3 by centrifugation for 30 minutes at 500 × g at 28
o
C. At 
16 hours post infection (h PI), the cells were treated with JO146 (0, 10, 50 and 100 µM) and 
DMSO (solvent) control (all experiments were done in triplicate, at least two separate 
experiments, with one representative experiment shown). At the completion of experiment 
(44 h PI unless otherwise stated) Chlamydia was harvested into storage medium (sucrose 
phosphate glutamate (SPG): 10 mM sodium phosphate (Na2HPO4), 250 mM sucrose 
(C12H22O11), 5 mM L-glutamine (C5H10N2O3)) for subsequent determination of infectious 
yield (IFU ml
-1 
as described below).  
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The duration of treatment required for JO146 effect was determined by removal of the 
compound from the cultures after 8 h treatment. At 16 h PI C. trachomatis cultures were 
treated with either 0 µM (media only), 100 µM JO146, or DMSO. At 24 h PI (i.e. 8 hours 
after treatment) treatments were removed by three sequential washes with pre-warmed media 
and the cultures continued until harvest into SPG media at 44 and 68 h PI.  
Inclusion forming units (IFU ml
-1
) were determined by subsequent passage culture on 
McCoy B cells. The SPG harvested cultures were lysed by sonication (Ultrasonic, Microson) 
and serially diluted onto McCoy B cultures. At 30 h PI, cultures were fixed and stained using 
immunocytochemistry for host nucleus and chlamydial inclusions, and examined by 
microscopy to enumerate inclusion forming units [18].  
2.2 Confocal microscopy  
McCoy B cells infected with C. trachomatis cultured on coverslips were used for 
confocal microscopy. At nominated time points the cells were fixed and 
immunocytochemistry conducted as previously described [12]. Confocal images were 
obtained using an Olympus FV1200 confocal laser scanning microscope (FluoView
®
 
FV1200, Olympus Corporation, Japan). Sizes of 30 independent inclusions for each treatment 
and time point were measured manually through the use of NIS-Elements Basic Research 3.2 
software.  
2.3 Western blot  
Cultures of T25 flasks of McCoy B cells infected with C. trachomatis were harvested 
for western blot analysis of the Major Outer Membrane protein (MOMP) and host β-actin 
after JO146 treatment at 16 h PI and harvested at 24 h PI. Western blots were conducted as 
previously described [22].   
2.4 Statistical analysis 
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Statistical analysis was performed using PRISM (GraphPad Software Inc., V7.0). 
Statistical significance was defined as p < 0.05. Statistical tests used and number of samples 
are indicated with each figure. 
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3. Results 
3.1. HtrA inhibition using JO146 during McCoy B culture of chlamydial isolates prevents 
chlamydial inclusion vacuole size development 
Our previous work using HEp-2 cells on C. trachomatis D (UW-3/Cx) a long term 
passaged isolate (referred to here as CtD) demonstrated that the inclusions decreased in size 
and were lost from the host cells [18]. Therefore, here we examined the morphology of the 
McCoy B cultures of the clinical isolates at 20, 24, and 40 h PI after JO146 treatment (16 h 
PI). JO146 treatment resulted in smaller inclusion vacuole sizes than the DMSO treated 
control cultures (Supplementary Fig. S1). .  
Inclusions sizes were measured to quantify these observations. This difference in 
inclusion size was apparent at 24 h PI although only four clinical isolates (1-079(1), 1-
079(13), 1-019(1), and 1-028(1)) showed statistically significant differences (p < 0.01) in the 
size of inclusions compared to DMSO control at this time point (Fig. 1). At 40 h PI, 
Chlamydia inclusions in the presence of JO146 were smaller than those formed in the control 
(DMSO-treated cells) in all clinical isolates as well as for the C. trachomatis D (p < 0.0001) 
(Fig. 1).  
 
3.2. JO146 treatment during mid-replicative phase of chlamydial development in McCoy B 
cells  resulted in a loss of infectious progeny for clinical isolates 
The effect of 16 h PI JO146 treatment on the development of infectious progeny was 
tested. No infectious progeny (44 h PI) were observed for all clinical isolates treated with 50 
and 100 µM JO146 except for isolate 1-017(13) (Fig. 2). For isolate 1-017(13) treatment with 
50 µM JO146 resulted in approximately 1 log less infectious yield compared to DMSO and 
media controls (p<0.001) and 100 µM resulted in a complete loss of infectious progeny as 
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consistent with the other clinical isolates. Treatment of the type strain C. trachomatis D with 
50 and 100 µM JO146 both resulted in ~1.5 log less infectious progeny compared to that 
observed in the DMSO control (p < 0.0001) (Fig. 2).  
The reduction in infectious progeny and reduced inclusion sizes (Fig. 1) should 
correlate with a decrease in the detection of chlamydial protein. A western blot to detect 
levels of MOMP 8 h after JO146 treatment, showed a reduction of MOMP levels compared 
to matched DMSO controls for most of the isolates (Supplementary Fig.S2). 
 
3.3. JO146 requires long treatment times to be effective against C. trachomatis in McCoy B 
cultures 
In order to determine if JO146 activity against chlamydial clinical isolates is 
effective with a short duration of treatment, we removed JO146 from the cultures 8 h after 
addition. This resulted in recovery of infectious progeny at 44 and 68 h PI in all clinical 
isolates (Fig. 3) in contrast to complete loss of progeny when the compound was left in the 
cultures (Fig. 2). In C. trachomatis clinical isolates 1-028(1) and 1-019(1), there were fewer 
infectious EBs in cells treated with 100 µM JO146 compared to the cells treated with 0 µM 
JO146 (media only) and DMSO controls either at 44 or 68 h PI (Fig. 3). A non-significant 
increase was observed in the number of infectious progeny at 68 h PI compared to 44 h PI 
with 100 M JO146 for isolates 1-017(13), 1-079(1), 1-048(1) and 1-020(1) (Fig. 3). Overall, 
an 8 h JO146 treatment of the cultures resulted in a minor loss of infectious progeny 
compared to when the compound was left in the cultures until the end of the developmental 
cycle (Fig. 2), suggesting that in McCoy B cultures there is a need for longer treatment 
duration for efficacy.   
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4. Discussion 
Here, we set out to determine if these previous observations of a critical function for 
HtrA during chlamydial replicative phase are relevant for recent clinical isolates of C. 
trachomatis. We demonstrate that addition of JO146 during mid-replicative phase resulted in 
a complete loss of infectious progeny if the compound is left in the cultures until the 
completion of the developmental cycle, providing preliminary support that the previous data 
in type strain cultures can be extrapolated to clinical isolates. 
These experiments were conducted in McCoy B cells, as consistent with other 
previously reported studies on C. trachomatis clinical isolates that all mainly use McCoy B 
cells (mouse fibroblasts) as host cells [19-21]. As we have not extensively studied the effect 
of JO146 on Chlamydia grown on McCoy B cells, we included C. trachomatis D as a control 
in all experiments. We previously demonstrated that treatment of HEp-2 cultures with the 
CtHtrA inhibitor JO146 resulted in diminishing chlamydial inclusion size, eventual loss of 
the inclusions, and loss of infectious progeny without being toxic to the host cells [8]. CtHtrA 
was found to be essential for the reversion and recovery to viability from penicillin 
persistence and during heat stress [12]. The critical role that CtHtrA plays during the 
replicative phase of the chlamydial developmental cycle was also demonstrated to be 
conserved among other C. trachomatis strains and other Chlamydia species such as C. 
pecorum, C. suis, and C. caviae [22]. The exact role of CtHtrA for the replicative phase 
remains unknown, and it is potentially and indirect effect of CtHtrA, and that one or more 
specific extra-cytoplasmic protein substrates that rely on CtHtrA for assembly is the required 
factor for replicative phase. 
The lack of lethality of 100 µM JO146 on type strain C. trachomatis D grown in 
McCoy B cells contrasts our previous result in HEp-2 cells, in which we observed complete 
loss of progeny for this same strain. These results suggest that there could be differences in 
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the pharmacokinetics of JO146 between mouse fibroblast (McCoy B) and human epithelial 
(HEp-2) cell lines, or in the chlamydial susceptibility during growth in these different cell 
lines. This difference also impacted on inclusion sizes actually sightly increasing over time 
during the cultures, again this may be due to differences in stability or degradation of JO146 
in the fibroblast cells. Previous studies have demonstrated different pharmacokinetics and 
bioactivity of drugs such as erythromycin in different mammalian cell lines [23, 24].  
In the present study the chlamydial inclusions were not completely lost from the host 
cells after JO146 treatment (in contrast to complete inclusion loss previously observed in 
HEp-2 cells), however these inclusions did not contain infectious progeny (Fig 1. and Fig 2.) 
[18]. Infectious progeny (with comparatively minor loss compared to controls) were observed 
for all strains tested when the cultures were treated with JO146 for 8 h at the replicative phase 
whereas there was lethality when the inhibitor was left in the cultures until the end of the 
developmental cycle. This result indicates that the inhibitory effect of JO146 is reversible by 
removal of the compound from the cultures and may be bacteriostatic, or may require longer 
than 8 h treatment to be effective in McCoy B cells. Here in McCoy B cells the inclusions fail 
to increase in size and do not make infectious progeny. This difference in the underlying 
process leading to loss of infectious progeny could be explained by several reasons; in these 
fibroblast-like cells perhaps the dosing is reduced due to cellular processes or once the 
Chlamydia in the inclusion have been inhibited by the JO146 treatment in HEp-2 a distinct 
host process than that of these fibroblasts is able to target the vacuoles. Nonetheless it is clear 
that CtHtrA is a valid possible target should future therapeutics need to be developed against 
Chlamydia, based on the effectiveness against these clinical isolates.  
The subtle differences in JO146 efficacy observed between the isolates and the type 
strain C. trachomatis D is not able to be explained by differences in CtHtrA amino acid 
sequence. The CtHtrA sequence is highly conserved with at most 4 amino acids different in 
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the 647 amino acid sequence across the published C. trachomatis genomes to date. The C. 
trachomatis genomes cluster into three predominant clades (LGV, T1, T2) [25], the CtHtrA 
sequences that we have determined so far from our clinical isolates are consistent with the T2 
clade (1-017(13), 1-017(1), 1-028(1), 1-048(1) (sequences will be published elsewhere). The 
amino acid variation is not near the residues that form active site where JO146 binds to the 
protein and is not likely to explain the variation. However, other differences that might 
impact on growth kinetics of pharmacokinetics of the drug on the chlamydial strains, as well 
as differences on the host cell factors do require further investigation in the future.  
 
5. Conclusions 
This preliminary study supports that JO146 is effective against recent clinical isolates 
of C. trachomatis. The data indicates that in vitro application of an inhibitor compound that 
targets CtHtrA during the replicative phase of recent clinical isolates of C. trachomatis 
prevents development of infectious progeny. CtHtrA therefore, could be a potential target for 
future drug development for C. trachomatis and we suggest that CtHtrA inhibition and JO146 
should be further investigated for improved drug development.  
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Fig. 1. Inclusion sizes at 20, 24 and 40 h PI for DMSO and JO146 treated isolates of C. 
trachomatis grown in McCoy B cells are shown in the graphs. Each isolate is shown in a 
separate graph: A. 1-017(13), B. 1-079(1), C. 1-028(1), D. 1-048(1), E. 1-020(1), F. 1-019(1), 
G. C. trachomatis D (UW-3/Cx). Statistical analysis was conducted using Two-Way 
ANOVA with Bonferroni’s multiple comparison tests. The bar colours represent treatment 
conditions; black: DMSO, and grey 100 M JO146. Data are presented as mean ± S.E.M 
(n=30), ** indicates p < 0.01, ****p < 0.0001.  
 
Fig. 2. Inclusion forming units after treatment with JO146 at 16 h PI or each of the strains is 
shown on the graph. The bars are shaded by grey scale (as indicated on the right) to represent 
the different concentrations of JO146. The identity of each of the isolates is indicated on the 
x-axis and the IFU ml
-1
 are indicated on the y-axis in log scale. The cultures were harvested 
at 44 h PI and the infectious progeny determined by measuring inclusion forming units that 
formed infections in a new monolayer of host cells. Statistical analysis was conducted using 
Two-Way ANOVA with a post hoc Bonferroni multiple comparison test relative to the 
DMSO control. Error bars represent the standard error of the mean (n=27) (non-logarithmic 
data), *** indicates p < 0.001, ****p < 0.0001. # indicates no detectable inclusion forming 
units. 
Fig. 3. Inclusion forming units ml
-1
 at 44 and 68 h PI after JO146 addition at 16 h PI and 
removal after 8 h (at 24 h PI). Conditions are represented by the coloured bars on the right 
(black: media only (0 M JO146), grey: DMSO, white: 100 M JO146). Each isolate is 
shown in a separate graph: A. 1-017(13), B. 1-079(1), C. 1-028(1), D. 1-048(1), E. 1-020(1), 
F. 1-019(1), G. C. trachomatis D (UW-E/Cx). The IFU ml
-1
 are indicated on the y-axis and 
the two time points (44 and 68 h PI) are indicated on the x-axis. The cultures were harvested 
at 44 h PI and the infectious progeny determined by measuring inclusion forming units that 
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formed infections in a new monolayer of host cells. Statistical analysis was conducted using 
Two-Way ANOVA with a post hoc Bonferroni multiple comparison test relative to the 
DMSO control. The error bars represent the standard error of the mean (n=27) (error bars are 
for the non-logarithmic scale),  ****p < 0.0001.  
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Supplementary material 
 
 
Supplementary Fig. S1. Confocal microscopy images of C. trachomatis clinical isolates 
treated with JO146 or DMSO at 16 h PI and examined at 20, 24, and 40 h PI. Representative 
images of control (DMSO treated) cultures are shown on the left panel while representative 
images of cultures treated with JO146 are shown on the right for each time point (time points 
indicated above figure) (strain identity indicated to left of the figure). The image colours are 
as follows, green; MOMP (major outer membrane protein); blue: host cell nucleus (stained by 
DAPI); red: β actin (stained by phalloidin 594). Scale bar (bottom left) indicates 10 µm.  
 
Supplementary Fig S2. Western blot for MOMP in cell lysates of JO146-treated and DMSO-
treated C. trachomatis clinical isolates in McCoy B cells. JO146 or DMSO were added at 16 
h PI and cells were harvested at 24 h PI (i.e. 8 hours after treatment). Treatments are 
indicated above each lane at the top of each isolate name. “+” denotes treatment with JO146 
and “-“ denotes treatment with DMSO control. Laboratory strain C. trachomatis D (UW-
3/Cx) (CtD) was included as a control strain. The size of relevant molecular weight markers 
are indicated to the right of the figure and the western blot identity (i.e. MOMP or β-actin) 
are indicated to the left.  
Figure
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altered the manuscript to be more concise and remove some text to fit this format. 
 
We appreciate the reviewers and your efforts to improve the manuscript. 
 
Yours sincerely, 
Willa Huston 
(on behalf of all authors) 
 
 
Reviewer #1:  
 
Major comments: 
3.1. paragraph 2. An increase of the inclusion size for all the strains tested between 20 and 
40h p.i. is observed suggesting that Chlamydia is able to grow but more slowly? How to 
explain that? A comment about that should be added in the article. 
Response: A sentence has been added to the discussion to speculate that the compound might 
be degrading more quickly in the McCoy cells (used in this study) than in HEp2 cells 
(previously used in our prior work.  
: This difference also impacted on inclusion sizes actually sightly increasing over time during 
the cultures, again this may be due to differences in stability or degradation of JO146 in the 
fibroblast cells. 
 
3.1. paragraph 2.  For the control CtD, a slight increase of the inclusion size is also observed. 
This result is in contrast to the previous article (S. Gloeckl et al., 2013) showing a slight 
decrease of the inclusion size. How to explain this discrepancy?  
Response: JO146 has different effectivity between McCoy cells and HEp2 cells, indicating 
that different mechanisms of compound absorption might be present for these two cell lines. 
We have found in our laboratory that JO146 is less effective when Chlamydia are grown in 
McCoy cells than in HEp2 cells. Hence, for this particular experiment, JO146 was less 
effective on CtD because McCoy cells were used in this study, compared to our previous 
article (Gloeckl et al, 2013) wherein JO146 was more effective on CtD and HEp2 cells were 
used. This has now been addressed in the discussion as above.  
 
3.2. paragraph 1. The absence of infectious progeny does not prove the lethal effect of the 
JO146. One hypothesis could be that the JO146 could just block/slow down the 
developmental cycle and delay/prevent reconversion into EBs. If there is no EBs at 44h p.i., 
there is no infection. In this trend, it could be interesting to make electron microscopy at 44h 
p.i. to evaluate the % of EBs versus RBs and compare treated versus non-treated infected 
cells. Moreover, to prove that the prolonged treatment with JO146 (16-44h) is really lethal for 
Chlamydia, the inhibitor can be removed (44h) and let the infected cells to grow again and 
finally evaluate the growth by qPCR, and infectious progeny yields.  
 
*Detailed Response to Reviewers
Response: These experiments could be interesting; however they are beyond the scope of this 
work, and as suggested by reviewer 2 this article has now been shortened to a short 
communication.  
 
3.2. paragraph 2. A relative quantification of the signal should be added to strengthen the 
decrease of the MOMP protein.  
Response: We agree this is a good idea, however, this was only at 8 hours and the most 
marked differences are likely to be later in the culture. We have actually used the advice or 
reviewer 2 and converted the manuscript to a short communication, meaning the western blot 
is now supplementary data. Therefore, given the shortening of the manuscript and that 
greater differences are likely to be not detectable until longer experiments that are not 
relevant to the scope of this paper we have excluded the addition of this densiometric data in 
the revised manuscript. 
 
3.3. This paragraph shows that the JO146 seems not to be lethal since when JO146 is 
removed (8h treatment) infectious progeny is obtained at 44 and 68h p.i.. It could be 
interesting to make a growth kinetic by quantifying bacterial genomic DNA by qPCR at 
different time post-infection and compare different treatment. 
 
Response: These experiments could be interesting; however they are beyond the scope of this 
work, and as suggested by reviewer 2 this article has now been shortened to a short 
communication 
 
Minor comments: 
2.1., paragraphe 2, line 4:  replace 'on at least two separate occasions' by 'on at least two 
separate experiments' 
Paragraph 2, line 4 has been changed to  
“on at least two separate experiments” 
 
 
2.1. paragraph 2, line 5: replace 'occasion' by 'experiment' 
Paragraph 2, line 5 has been changed to 
“experiment” 
 
2.3. align the paragraph 
The paragraph has been aligned.  
 
Lethal or lethality should be replaced by 'complete inhibition of the developmental cycle' or 
'complete loss of infectious progeny' 
 
This has been done throughout the results, discussion, and conclusion sections. 
 
Reviewer #2:  
I suggest that this work may be presented as a short form paper. The microscopy panel in Fig 
1 and measurement of inclusion sizes in Fig 2 and western blot in Fig 4 are mainly redundant 
information so Fig 1 and Fig 4 may be provided as supplementary information. 
Response: The paper has been changed from a journal article into a short communication. 
Figures 1 and 4 have been made as supplementary information.  
 
 
Specific comments 
 
The clinical isolates tested were in fact more sensitive to J0146 compared to a lab strain. 
However the potency of J0146 was lower than previously shown for the lab strain. The 
authors draw the conclusion that J0146 is less potent in Chlamydia grown in McCoy cells 
compared to Chlamydia grown in HEp-2 cells although this particular comparison has not 
been performed. Batch variation and storage may also affect the potency of compounds. To 
draw that conclusion the authors need to include testing of the same batch of J0146 for the 
lab strain in HEp-2 cells, and present it at least as a comment in the text. 
Response: We agree that different batches can have different inhibitory effect on Chlamydia 
strains. However, we have previously observed many times in our laboratory that JO146 
stocks of the same batch have different inhibitory effect on Chlamydia cultured in different 
cells lines, McCoy and HEp2. Whilst we agree that different batches of the compound may be 
a factor that contributes to its varying effectivity in McCoy and HEp2, the differences in the 
pharmacokinetics (absorption, distribution, metabolism and excretion) of JO146 between 
HEp2 and McCoy cells would have been a bigger factor that affects its varying effectivity 
between these two cell lines. 
 
Given this paper is not a short communication format the inclusion of this additional 
experiment is beyond the scope of the manuscript. 
 
The authors discuss that uptake and elimination of compound may be different in different 
cell lines. Antimicrobial susceptibility testing is not standardized for Chlamydia and since 
clinical strains are usually isolated on McCoy cells testing in this cell line is relevant. The 
authors' conclusion that it is important to test novel compounds not just in different 
Chlamydia strains but also in different cell lines should be more clearly written in the 
discussion. 
 
Response: the following sentence has been added to the discussion: 
However, other differences that might impact on growth kinetics of pharmacokinetics of the 
drug on the chlamydial strains, as well as differences on the host cell factors do require 
further investigation in the future. 
 
The latter part of the last sentence in the abstract "…and suggests the importance of further 
investigation in additional cell lines and chlamydial strains." needs to be rephrased. This 
particular inhibitor has been investigated in quite a few strains and now a couple of different 
cell lines. What is really interesting is why the effect is different in different cell lines and of 
course development of more potent HtrA inhibitors. 
 
Response: The final sentence of the abstract has been edited to state: 
„of JO146 as a lead compound‟.  
 
Page 5 section 2.1: No reference is given for compound J0146. 
Response: The appropriate references has been inserted. 
 
Page 19 Figure legend 3: It needs to be clarified that the data is on formation of infectious 
progeny. 
Response: Now Fig 2 in revised manuscript 
The following line has been made added to the figure legend for Figure 3 - now figure 2.  
“The cultures were harvested at 44 h PI and the infectious progeny determined by measuring 
inclusion forming units that formed infections in a new monolayer of host cells.’ 
 
Page 20 Figure legend 5: Is this also infectious progeny? It is not clear from the figure 
legend. 
The following line has been made added to the figure legend for Figure 5 - now figure 3.  
“The cultures were harvested at 44 h PI and the infectious progeny determined by measuring 
inclusion forming units that formed infections in a new monolayer of host cells.’ 
 
Reviewer #3:  
 
1. The first sentence of the introduction where they say it is the most commonly reported 
sexual pathogen should be cited OR changed so the language is not as strong language. 
Response:  
The phrase in paragraph 1 section 1 has been changed to  
“a commonly” From “the most commonly” 
 
2. Section 2.3 of the methods is indented improperly 
Response: Section 2.3 of the Methods has been properly aligned. 
 
3. In results section 3.1 CtD strain should be defined in the text, at its first use is before 
its mention the legend of figure 4 (is it a lab strain or another clinical strain?) 
Response:  
The following line has been added to the first line in paragraph 1 section 3.1 after the 
phrase “C. trachomatis D (UW-3/Cx)” “(CtD), a long term passaged isolate” 
Consequently, this phrase has been deleted in paragraph 2 section 3.1 to avoid 
repetition.  
 
4. Page 9 line 3 should be referring to figure 3 not 4 
Response: Page 9 line 3 has been changed to  
“Figure 2” From: “Figure 4” (now fig 2 due to changing to short communication) 
 
5. In Figure 4, it should be indicated which band is which protein on the actual figure if 
possible 
Response: Figure 4 (Supplementary Fig S2 now) has been edited and a new figure which 
indicates which band is which protein, and with appropriate band size has been added 
 
6. It is mentioned throughout the text that this drug kills Chlamydia, however there is no 
evidence that suggests this, as there is more evidence that JO146 is a bacteriostatic as oppose 
to a bacteriocidal antimicrobial. These statements should be changed throughout the entire 
paper as this is extremely misleading.   
   
Response: As per previous reviewer - we have removed all mention of the word lethal 
and changed to loss of infectious progeny. 
 
7. In the conclusion section there is a red line at the title of section 5 
Response: this red line has been removed.  
 
8. I was wondering if the authors could comment or speculate on a potential mechanism 
of action for how JO146 inhibits Chlamydial cell division, perhaps they could comment on 
the role of the protease CtHtrA in the bacteria's cell cycle.  
Response: The following comment has been added to the discussion. 
The exact role of CtHtrA for the replicative phase remains unknown, and it is potentially and 
indirect effect of CtHtrA, and that one or more specific extra-cytoplasmic protein substrates 
that rely on CtHtrA for assembly is the required factor for replicative phase. 
 
 
Experiments 
1. Figure 4, the differences observed are negligible, if a different western blot could be 
provided, where the differences are more apparent that would make this much more 
acceptable, alternatively this could be supplemented with RT-qPCR for a constitutively 
expressed gene to demonstrate this difference. 
 
Response: Please see previous comments. This is a good suggestion however it is beyond the 
scope of this work which was simply aiming to demonstrate effectiveness against clinical 
isolates rather than mechanism of activity. This manuscript has now been shortened to a short 
communication format to inclusion of these additional experiments is not valid. 
 
 
Reviewer #4:  
 
The authors reported that Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, known to 
inhibit Chlamydia trachomatis growth in cell culture, also inhibited the growth of Chlamydia 
trachomatis clinical isolates in cell culture. The result is not surprising given that CtHtrA is a 
highly conserved protease. Thus, there is not enough new information in the manuscript. To 
show the clinical relevance of the inhibitor, the authors should test the inhibitor in animal 
models. 
 
Response: The animal model is beyond the scope of this publication. We have presented the 
mouse model work previously in the 2013 Mol Micro publication. 
 
